EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Gremlin1: a BMP antagonist with therapeutic potential in Oncology

Zhao Jin, Yanshuo Cao

Investigational New Drugs · 2024-12 · 42 (6) · 716-727

DOI: 10.1007/s10637-024-01474-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Investigational New Drugs, online erschienen am 30.09.2024. Verfasst von Zhao Jin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cance…. Hauptthemen laut MEDLINE: Neoplasms, Intercellular Signaling Peptides and Proteins, Bone Morphogenetic Proteins. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 95 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gremlins, originating from early 20th-century Western folklore, are mythical creatures known for causing mechanical malfunctions and electronic failures, aptly dubbed "little devils". Analogously, GREM1 acts like a horde of these mischievous entities by antagonizing the bone morphogenetic protein (BMP signaling) pathway or through other non-BMP dependent mechanisms (such as binding to Fibroblast Growth Factor Receptor 1and Epidermal Growth Factor Receptor) contributing to the malignant progression of various cancers. The overexpression of GREM1 promotes tumor cell growth and survival, enhances angiogenesis within the tumor microenvironment, and creates favorable conditions for tumor development and dissemination. Consequently, inhibiting the activity of GREM1 or blocking its interaction with BMP presents a promising strategy for suppressing tumor growth and metastasis. However, the role of GREM1 in cancer remains a subject of debate, with evidence suggesting both oncogenic and tumor-suppressive functions. Currently, several pharmaceutical companies are researching the GREM1 target, with some advancing to Phase I/II clinical trials. This article will provide a detailed overview of the GREM1 target and explore its potential role in cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsIntercellular Signaling Peptides and ProteinsBone Morphogenetic ProteinsHumansAnimalsAntineoplastic AgentsSignal TransductionTumor Microenvironment

Stichwörter der Autor:innen

BMPCancerFibroblastGremlin-1Tumor microenvironment

Substanzen

GREM1 protein, humanIntercellular Signaling Peptides and ProteinsBone Morphogenetic ProteinsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
  • Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China. yanshuo.cao@bjmu.edu.cn.

Zitieren

APA

Jin, Z., & Cao, Y. (2024). Gremlin1: a BMP antagonist with therapeutic potential in Oncology. Investigational New Drugs, 42(6), 716-727. https://doi.org/10.1007/s10637-024-01474-8

Vancouver

Jin Z, Cao Y. Gremlin1: a BMP antagonist with therapeutic potential in Oncology. Investigational New Drugs. 2024;42(6):716-727. doi:10.1007/s10637-024-01474-8

BibTeX
@article{Jin2024,
  author = {Jin, Zhao and Cao, Yanshuo},
  title = {Gremlin1: a BMP antagonist with therapeutic potential in Oncology},
  journal = {Investigational New Drugs},
  year = {2024},
  volume = {42},
  number = {6},
  pages = {716--727},
  doi = {10.1007/s10637-024-01474-8}
}
Kostenlos starten →